From the PWN editor’s desk, today we introduce weekly briefings, a series of noteworthy developments on health, wellness and general interest stories for people living and dealing with pituitary conditions.
From Obesity News Today: Researchers targeting protein that promotes weight gain. The discovery helps explain why overweight people find it hard to loose weight. Could lead to the development of new drugs to help reduce obesity or control weight loss. Read the article here.
From the Endocrine Society 2015 annual meeting this is an interesting lecture by Dr John A.H. Wass from Oxford University in the UK discussing challenging cases in the management of acromegaly. There is an interesting discussion on heredity in Acromegaly and Gigantism. Click here to listen to the lecture:
Our friends at Berkeley Wellness published a list of the top 11 health stories for 2015. Of particular note was an article on endocrine disruptors; these are chemical that interfere with the function of human hormones. Other stories included: dietary guidelines, warning on pain relievers, and my favorite, an article on the protein craze proving yet again that science is no match for a good marketing blitz. Read it here:
PRI (Public Radio International) in their program Science Friday asked “Are we close to curing cancer? This is a subject that has given researchers new hope that new immune therapies will make a real dent in the war on cancer. The idea behind these drugs is to use the person’s own immune system to attack the cancer. Amazing stuff. Read it here:
The American Association of Clinical Endocrinologists and the American College of Endoncrinology AACE/ACE published an update of the algorithm for the comprehensive management of persons with type 2 diabetes. The algorithm was developed to provide clinicians with a practical guide that considers the whole patient, their spectrum of risks and complications, and evidence-based approaches to treatment. Since originally drafted in 2013, the algorithm has been updated as new therapies, management approaches, and important clinical data have emerged. The 2016 edition includes a new section on lifestyle therapy as well as discussion of all classes of obesity, antihyperglycemic, lipid-lowering, and antihypertensive medications approved by the U.S. Food and Drug Administration (FDA) through December 2015. You can read more here:
© 2016, Pituitary World News. All rights reserved.